Adding palmitoleic acid to infliximab for Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This study tests whether adding a natural fatty acid (palmitoleic acid) to a standard Crohn's treatment (infliximab) is better at healing the lining of the intestine. It aims to see if this combination can calm the disease and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need a confirmed diagnosis of Crohn's disease.
- Your Crohn's disease must be active, which we check with a symptom score called the CDAI (between 220 and 450).
- You must not have used certain biologic medicines (like infliximab, adalimumab) or fish oil/lipid supplements in the last 8 weeks.
- You must not have had any Crohn's-related bowel surgery, or have active infections or a history of cancer.
- You must be willing to have up to 3 endoscopies (a test with a camera to look inside your bowel).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
This study tests whether adding a specific gut bacteria (Akkermansia muciniphila) to the standard Crohn's treatment infliximab helps heal the intestinal lining better. This could improve long-term control of Crohn's disease.
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.